Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: Analysis of the 1988-2003 SEER data

被引:242
作者
Gnerlich, Jennifer
Jeffe, Donna B.
Deshpande, Anjali D.
Beers, Courtney
Zander, Christina
Margenthaler, Julie A.
机构
[1] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA
[3] St Louis Univ, Sch Publ Hlth, Dept Community Hlth, St Louis, MO 63104 USA
关键词
stage IV breast cancer; SEER data; survival; surgery;
D O I
10.1245/s10434-007-9438-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Primary treatments for stage IV breast cancer are chemotherapy and radiation, with surgery usually reserved for tumor-related complications. We sought to determine whether surgical removal of the primary tumor provides a survival advantage for women with metastatic breast cancer. Methods: We conducted a retrospective, population-based cohort study by using the 19882003 Surveillance, Epidemiology, and End Results (SEER) program data. By use of multivariate Cox regression models, overall survival in women with stage IV disease was compared between women who underwent surgical excision of their breast tumor with women who did not, controlling for potential confounding demographic, tumor- and treatment-related variables, and propensity scores (accounting for variables associated with the likelihood of having surgery). Results: Of 9734 SEER patients with stage IV breast cancer, 47% underwent breast cancer surgery and 53% did not. Median survival was longer for women who had surgery than for women who did not, both among women who were alive at the end of the study period (36.00 vs. 21.00 months; P <.001) and among women who had died during follow-up (18.00 vs. 7.00 months; P <.001). After controlling for potential confounding variables and propensity scores, patients who underwent surgery were less likely to die during the study period compared with women who did not undergo surgery (adjusted hazard ratio, .63, 95% confidence interval, .60-66). Conclusions: Analysis of the 1988-2003 SEER data indicated that extirpation of the primary breast tumor in patients with stage IV disease was associated with a marked reduction in risk of dying after controlling for variables associated with survival.
引用
收藏
页码:2187 / 2194
页数:8
相关论文
共 31 条
[1]  
Abdalla EK, 2004, ANN SURG, V239, P818, DOI 10.1097/01.sla.0000128305.90650.71
[2]   Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor [J].
Babiera, GV ;
Rao, R ;
Feng, L ;
Meric-Bernstam, F ;
Kuerer, HM ;
Singletary, SE ;
Hunt, KK ;
Ross, MI ;
Gwyn, KM ;
Feig, BW ;
Ames, FC ;
Hortobagyi, GN .
ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (06) :776-782
[3]   Facts and controversies in systemic treatment of metastatic breast cancer [J].
Bernard-Marty, C ;
Cardoso, F ;
Piccart, MJ .
ONCOLOGIST, 2004, 9 (06) :617-632
[4]   Variable selection for propensity score models [J].
Brookhart, M. Alan ;
Schneeweiss, Sebastian ;
Rothman, Kenneth J. ;
Glynn, Robert J. ;
Avorn, Jerry ;
Sturmer, Til .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2006, 163 (12) :1149-1156
[5]   Does local surgery have a role in the management of stage IV breast cancer? [J].
Carmichael, AR ;
Anderson, EDC ;
Chetty, U ;
Dixon, JM .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2003, 29 (01) :17-19
[6]   What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? [J].
Chi, D. S. ;
Eisenhauer, E. L. ;
Lang, J. ;
Huh, J. ;
Haddad, L. ;
Abu-Rustum, N. R. ;
Sonoda, Y. ;
Levine, D. A. ;
Hensley, M. ;
Barakat, R. R. .
GYNECOLOGIC ONCOLOGY, 2006, 103 (02) :559-564
[7]   Circulating tumor cells, disease progression, and survival in metastatic breast cancer [J].
Cristofanilli, M ;
Budd, GT ;
Ellis, MJ ;
Stopeck, A ;
Matera, J ;
Miller, MC ;
Reuben, JM ;
Doyle, GV ;
Allard, WJ ;
Terstappen, LWMM ;
Hayes, DF .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (08) :781-791
[8]   Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease [J].
Danna, EA ;
Sinha, P ;
Gilbert, M ;
Clements, VK ;
Pulaski, BA ;
Ostrand-Rosenberg, S .
CANCER RESEARCH, 2004, 64 (06) :2205-2211
[9]  
Dauplat J, 2000, SEMIN SURG ONCOL, V19, P42, DOI 10.1002/1098-2388(200007/08)19:1<42::AID-SSU7>3.0.CO
[10]  
2-M